Tolga Tanguler

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, shares his insights on commercializing RNAi therapies. He discusses how these treatments navigate health insurance reimbursement systems and the innovative use of value-based contracts. Tanguler explores the complexities of expanding from rare diseases to larger patient populations, the evolution of biopharmaceutical sales strategies, and the importance of strategic partnerships in the industry. With a focus on enhancing patient adherence and accessibility, he outlines future priorities for biotech innovations.